Development and Validation of a Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

Information

  • Research Project
  • 10224321
  • ApplicationId
    10224321
  • Core Project Number
    R01HL148437
  • Full Project Number
    5R01HL148437-02
  • Serial Number
    148437
  • FOA Number
    PA-19-056
  • Sub Project Id
  • Project Start Date
    8/1/2020 - 3 years ago
  • Project End Date
    7/31/2024 - a month from now
  • Program Officer Name
    VUGA, LOUIS J
  • Budget Start Date
    8/1/2021 - 2 years ago
  • Budget End Date
    7/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    02
  • Suffix
  • Award Notice Date
    7/21/2021 - 2 years ago
Organizations

Development and Validation of a Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

PROJECT SUMMARY/ABSTRACT: Hypersensitivity pneumonitis (HP) is an immunologically mediated form of lung disease, resulting from inhalational exposure to a large variety of antigens. For unknown reasons, a subgroup of patients with HP without a known inciting antigen exposure develops chronic disease with progressive pulmonary fibrosis (the leading cause of death). Accurately identifying patients at risk of disease progression is necessary for prognosis and therapy. The objective of this proposal is to refine our current clinical risk stratification by identifying and validating a transcriptomic signature from peripheral blood mononuclear cells in patients with chronic HP that is predictive of disease progression. We hypothesize that the clinical course of chronic HP is associated with a peripheral blood gene expression signature of risk that can be used to refine the prognosis and predict the clinical outcome. Guided by strong preliminary data, this hypothesis will be tested by two specific aims: i) Establish transcriptomic signatures at time of initial presentation in peripheral blood mononuclear cells from patients with chronic HP in a Discovery cohort and then validate the signature in an independent chronic HP replication cohort; and ii) Establish a time-course transcriptomic profile predictive of disease progression in the Discovery cohort and validate the signature profile in the independent chronic HP replication cohort. pursuing The proposed research is significant because it will provide the knowledge that will enhance our ability to predict disease progression, a level of prognostication which is not possible with current clinical measures alone. Relevance to Public Health: This is an important and under-investigated area that has the potential to fundamentally advance our understanding of the pathobiology of disease progression and provide the groundwork to define molecular targets relevant to chronic HP disease progression.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
    552229
  • Indirect Cost Amount
    175818
  • Total Cost
    728047
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    838
  • Ed Inst. Type
  • Funding ICs
    NHLBI:728047\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    NATIONAL JEWISH HEALTH
  • Organization Department
  • Organization DUNS
    076443019
  • Organization City
    DENVER
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    802062761
  • Organization District
    UNITED STATES